One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : N. Lynn Henry Vered Stearns
- چاپ و سال / کشور: 2010
Description
Adjuvant endocrine therapy for breast cancer is associated with significant improvements in disease-related outcomes. Five years of tamoxifen therapy is associated with 41 and 34% reductions in annual breast cancer recurrence and death rate, respectively [1]. Adjuvant aromatase inhibitor (AI) use instead of or in sequence with tamoxifen is slightly superior to single agent tamoxifen in terms of improvement in disease-free survival, but with comparable overall survival benefit [2, 3]. Despite these beneficial outcomes, up to 50% of women discontinue these potentially life-saving medications prior to completion of the recommended 5 years of therapy [4–7]. One of the main reasons for treatment discontinuation is medication-associated side effects that may negatively impact quality of life. Few studies reported to date have compared outcomes and emergence of symptoms in women with early stage breast cancer treated with different AIs.
Breast Cancer Res Treat (2011) 125:751–753 DOI 10.1007/s10549-010-1206-3 Received: 2 September 2010 / Accepted: 28 September 2010 / Published online: 13 October 2010 Springer Science+Business Media, LLC. 2010
